Thinly traded NGM Biopharmaceuticals (NASDAQ:NGM) perks up 4% premarket on light volume in reaction to final data from Cohort 4 of the 24-week Phase 2 clinical trial evaluating aldafermin 1 mg in patients with nonalcoholic steatohepatitis (NASH). This group consisted of NASH patients with stage 3 (advanced) fibrosis.
30% of these patients receiving aldafermin 1 mg experienced more than a one-stage improvement in fibrosis without worsening of NASH compared to 0% in the control arm.
An analysis of the responders who achieved at least a 30% reduction in liver fat content (LFC) showed that 46% experienced at least on one-stage improvement in fibrosis without worsening of NASH compared to 0% for placebo.
Aldafermin (formerly NGM282) is an engineered variant of a hormone called fibroblast growth factor 19 (FGF19) secreted by the gall bladder that plays a key role protecting the liver.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.